🏛️ Verified NIH Record • Updated 2025-05-07

ATG Plus PTCy vs ATG for CGVHD Prophylaxis (NCT04202835)

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: McMaster University

🩺 Plain-English Summary (8th-Grade Level)

A Randomized Pilot Trial to test the feasibility of comparing anti-thymocyte globulin plus post transplant cyclophosphamide with anti-thymocyte globulin alone to prevent chronic graft versus host disease.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (9 items) and avoid the listed exclusions (17 items).

Location: Kinghorn Cancer Centre, St Vincent's Health Network — Darlinghurst, New South Wales

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • The participant is HIV antibody positive
  • The participant has a hypersensitivity to rabbit proteins or Thymoglobulin® pharmaceutical excipients, glycine or mannitol.
  • The participant has active or chronic infection (i.e. infection requiring oral or IV therapy)
  • The participant (if female and of childbearing potential) is pregnant or breast-feeding at the time of enrollment
  • The participant (if female and of childbearing potential) does not agree to use an adequate contraceptive method from the time of enrollment until a minimum of one year following transplant3
  • The participant (if male and fertile) does not agree to use an adequate contraceptive method from the time of enrollment until a minimum of one year following transplant3
  • The participant has urinary outflow obstruction
  • The participant is in poor condition (determined per institutional guidelines)
  • The participant has acute leukemia in relapse
  • The participant has myelodysplastic syndrome with \> 10% marrow blasts
  • The participant is having their second transplant

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (9 Sites)

  • Kinghorn Cancer Centre, St Vincent's Health Network — Darlinghurst, New South Wales
  • Royal North Shore Hospital — St Leonards, New South Wales
  • Australasian Leukaemia and Lymphoma Group — Melbourne, Victoria
  • CancerCare Manitoba — Winnipeg, Manitoba
  • Queen Elizabeth II Health Sciences Centre — Halifax, Nova Scotia
  • Juravinski Hospital and Cancer Centre — Hamilton, Ontario
  • London Health Sciences Centre — London, Ontario
  • Hôpital de l'Enfant-Jésus — Québec, Quebec
  • Saskatchewan Cancer Agency — Saskatoon, Saskatchewan

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗